TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00778700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Ruxolitinib phosphate cream
Study: NCT02861482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duratocin
Description: using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
Study: NCT01896609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bon one in Arm 3
Description: Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xerovirinc in Arm 2
Description: Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
Study: NCT02861482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Massage
Description: continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: B-lynch Suture
Description: One of conservative surgical procedures if Bakri Balloon didn't work

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Artery Embolization using sponges
Description: One of conservative surgical procedures if Bakri Balloon didn't work

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: One of conservative surgical procedures if Bakri Balloon didn't work
Study: NCT02861482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Hysterectomy with all the above measures not working

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blood Product
Description: transfusion of blood product if necessary no matter which surgical procedure has been taken
Study: NCT00816075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: distilled water
Description: we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
Study: NCT01742338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Corticosteroids
Study: NCT02952014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C4 Extreme
Description: Pre-Workout Dietary Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C4 Extreme (without Advantra Z
Description: Pre-Workout Dietary Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-Workout Dietary Supplement
Study: NCT03754894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ready made plastic stent application
Description: full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple interrupted sutures
Description: full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
Study: NCT04950569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
Study: NCT02481609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Study: NCT02697188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Description: Single-day dose as QD or BID for 3 of 5 crossover periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone enanthate
Description: Single-day dose for 2 of 5 crossover periods
Study: NCT01453907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETI-204, Anthim
Description: intravenously, single dose

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: intravenously, single dose
Study: NCT03578328

Intervention type: PROCEDURE
Intervention: targeted temperature management
Description: Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
Study: NCT04369625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIMPS-T
Description: CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIMPS-P
Description: CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIMPS-MFT-group
Description: The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCHIMPS
Description: iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
Study: NCT03664765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UA and RMT
Description: daily oropharyngeal and respiratory muscle exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham exercise
Description: Daily sham exercises
Study: NCT00383162

Intervention type: DRUG
Group type: OTHER
Intervention: Combination Product (sumatriptan succinate / naproxen sodium)
Description: Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.

Intervention type: DRUG
Group type: OTHER
Intervention: Combination Product (sumatriptan succinate / naproxen sodium)
Description: Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo tablet.
Study: NCT04260945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20 Dual-CAR-T cells
Description: CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
Study: NCT00333918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromfenac ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Study: NCT02696239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-lock suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl Suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lapra-Ty II
Study: NCT03579641

Intervention type: DEVICE
Intervention: HeartLogic Sensors
Description: HeartLogic Sensors
Study: NCT03468647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soles
Description: Volunteer must walk this this connected seamless to measure different walking parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weighting machine
Description: This weighting machine measure weight evolution and equilibrate of volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gripping force
Description: this machine measure the gripping force of volunteer
Study: NCT04899453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
Study: NCT01407445

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet/ oral/ 3 times a day for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tribulus terrestris
Description: 1 tablet of 250mg/ oral/ 3 times a day for 90 days
Study: NCT01558050

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: red rice supplement
Description: patricipants take a red rice supplement or placebo daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red rice supplement
Description: patricipants take a red rice supplement or placebo daily for 8 weeks
Study: NCT01069705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder
Description: Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
Study: NCT03799276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opticare study
Description: Each patient will be evaluated by~* An HIV physician~* A nurse~* A social worker~* A psychological therapist~* A cultural mediator/member of patients community if needed for migrants~Following these interviews and visits, a multisciplinary team will define for each patient an individualized OPTICARE program based on the following items: clinical, psychological/psychiatric, social status and follow up visits will be planned with the patient.~Regular (Day 15 and monthly) phone calls will be set up during the first six months of the OPTICARE program, to assess the clinical status and ART adherence.~Patients will have their medical, biological and social status assessed through visits at W4, W12, W24, W36 (medical and social status only) and W 48 with all members of the OPTICARE team.
Study: NCT00995995

Intervention type: DRUG
Intervention: Rosiglitazone
Description: Rosiglitazone
Study: NCT03534622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days
Study: NCT03624127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Specified dose on specified days
Study: NCT00070265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04484454

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProdromeNeuro Omega 3 Oil Nutritional Supplement
Description: ProdromeNeuro is an algae-derived Omega 3 oil nutritional supplement product comprised of naturally occurring alkylglycerol and natural fatty acids. ProdromeNeuro functions as a natural plasmalogen precursor which can be administered orally.
Study: NCT00912990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: One intravenous dose: 0.2mg/kg/dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: One Intravenous dose
Study: NCT01896609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xerovirinc in Arm 2
Description: Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin in Arm 1
Description: Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
Study: NCT03638310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intratympanic application of gentamicin
Description: under local anesthesia is gentamicin instilled through tympanic membrane to tympanic cavity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microsurgical removal of vestibular schwannoma
Description: surgery under general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microsurgical removal of vestibular schwannoma
Description: surgery under general anesthesia
Study: NCT02046148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS trivalent vaccine
Description: Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection - Normal saline
Study: NCT04824170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Glide
Description: hot pack and cervical traction is applied for 10-15 min.Group A received Neural mobilization of median nerve which includes gliding and sliding was given,therapist stood on the patient \& affected side besides the patient, patient'S shoulder was depressed with one hand and elbow was moved in 90 degree flexion, forearm supination, extend the wrist and fingers with other hand. Then patient arm was moved into 90 degree abduction and then sliding or gliding of nerve was applied. Sliding was applied with elbow extension and wrist flexion and elbow flexion with wrist extension. 6 sets were performed. Each set was performed for 60 seconds, for alternative days in week for 4 weeks and then progressed to gliding/tensioning technique when symptoms improved

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic stabilization technique
Description: This group was receiving (PNF) Rhythmic stabilization technique with base line treatment.~Subject was lying in spine position on the treatment table and therapist resist an isometric contraction of agonist muscle group.pt maintain this position for 10 sec without trying to move and 12-15 repetitions were performed with 30 sec rest. Each therapeutic session treatment was focused on facilitation of neck stabilizers, improving neck stability, coordination, decreasing pain and improving postural control
Study: NCT01012011

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Daily dose, dosage frequency and duration will be decided by physicians.
Study: NCT04267991

Intervention type: DRUG
Intervention: Tacrolimus ointment
Description: Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.

Intervention type: PROCEDURE
Intervention: phototherapeutic keratectomy
Description: Patients underwent transepithelial PTK for subepithelial infiltrates.
Study: NCT04131634

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation
Description: A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
Study: NCT02211131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10\^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10\^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immediate surgical resection of melanoma lesion(s)
Description: Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
Study: NCT03340025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Single Use Negative Pressure Wound Therapy System
Description: Class II negative pressure wound therapy powered suction pump

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: xeroform gauze
Description: traditional surgical dressing of xeroform gauze and padding
Study: NCT00528723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol 100 mcg
Description: To be used as needed for symptom relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol 100 mcg
Description: To be used as needed for symptom relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/salbutamol HFA pMDI
Description: Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP/salbutamol CFC pMDI
Description: Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
Study: NCT02391103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compex 3 Professional (CefarCompex Medical AB) stimulator
Description: NMES

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-stimulation
Description: no electricity applied
Study: NCT03360370

Intervention type: OTHER
Intervention: Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)
Description: This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities.
Study: NCT03350854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Preference in Treatment Decision Making
Description: The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
Study: NCT03149692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penile allograft transplantation
Description: Proof of concept of surgical procedure
Study: NCT02373787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: creos xenoprotect
Description: Implant placement with simultaneous bone augmentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Gide
Description: resorbable collagen membrane
Study: NCT03188744

Intervention type: OTHER
Intervention: Assessment of the pelvic floor function
Description: Vaginal palpation and perineometry.

Intervention type: OTHER
Intervention: Assessment of the pelvic floor function
Description: Vaginal palpation and perineometry.

Intervention type: OTHER
Intervention: Assessment of the pelvic floor function
Description: Vaginal palpation and perineometry.

Intervention type: OTHER
Intervention: Questionnaire application
Description: Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.

Intervention type: OTHER
Intervention: Questionnaire application
Description: Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.

Intervention type: OTHER
Intervention: Questionnaire application
Description: Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.

Intervention type: OTHER
Intervention: Questionnaire application
Description: Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
Study: NCT03491527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crown cimentation
Description: Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crown cimentation
Description: Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal adjustment
Description: Analysis of the occlusion with carbon paper.
Study: NCT03825016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Lidocaine infusion on hystroscopic media during office hystroscopy
Study: NCT02606188

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified High-flow nasal cannula
Description: Modified High-flow nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal cannula
Description: Conventional oxygen therap
Study: NCT03491527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal adjustment
Description: Analysis of the occlusion with carbon paper.
Study: NCT01230073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-Monitoring
Description: Home-Monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-Monitoring
Description: Home-Monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up by Home-Monitoring
Description: Follow-up by Home-Monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up by Home-Monitoring
Description: Follow-up by Home-Monitoring
Study: NCT03872739

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: enhanced computed tomography
Description: undergoing enhanced computed tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enhanced computed tomography
Description: undergoing enhanced computed tomography